Hipertensión Pulmonar del Grupo 3, Asociada a EPOC y EPID

26 March 2026

This webinar is part of the Latin America Task Force series and focuses on Group 3 pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).

The session was delivered in Spanish and brings together international experts to explore the impact of the updated haemodynamic definition of PH (mPAP >20 mmHg, PVR >2), which has led to increased detection in COPD, ILD, and mixed phenotypes such as CPFE. The recording covers diagnosis, interpretation of investigations, and current treatment approaches, alongside expert-led case discussions.

This PVRI webinar was hosted live on 18 March 2026, 15:00 GMT.

Other materials on this topic

13 May 2026

Fine Particulate Exposure During Pregnancy Impacts on Perinatal Complications in Deeply Phenotyped Preterm Infants With Significant Immaturity

The identification of ubiquitous risk factors determining long-term morbidity is crucial in infants born prematurely when aiming to develop prevention strategies.

Pulmonary Circulation

8 May 2026

Early changes in the pulmonary vasculature in response to high altitude: mechanisms and potential treatments

Part of the 'Hypoxia in pulmonary vascular research – altitude and beyond' webinar series by the High Altitude Task Force, who raise awareness and understanding of PH linked to high altitude and organise scientific conferences in regions affected by high altitudes.

IDDI Workstream or Task Force Learning

20 March 2026

Pregnancy Outcomes Following Macitentan or Bosentan Exposure Before or During Pregnancy: Review of Cases Reported to the Manufacturer's Global Safety Database

Pregnancy in pulmonary arterial hypertension (PAH) is associated with substantial risks. Endothelin receptor antagonists (ERAs), including macitentan and bosentan, are contraindicated in pregnancy due to teratogenic effects observed in animal studies.